AXIM Biotechnologies, Inc.
AXIM · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $70 | $40 | $9 | $60 |
| % Growth | 78.3% | 345.3% | -85.3% | – |
| Cost of Goods Sold | $440 | $0 | $426 | $0 |
| Gross Profit | -$369 | $40 | -$417 | $60 |
| % Margin | -524.1% | 100% | -4,701.4% | 100% |
| R&D Expenses | $40 | $125 | $154 | $285 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,354 | $2,238 | $4,082 | $5,668 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $427 | $426 | $1,836 |
| Operating Expenses | $1,394 | $2,790 | $4,662 | $7,789 |
| Operating Income | -$1,763 | -$2,751 | -$4,653 | -$7,985 |
| % Margin | -2,502.3% | -6,961% | -52,425.6% | -13,207.1% |
| Other Income/Exp. Net | -$1,749 | -$5,309 | -$1,590 | -$2,049 |
| Pre-Tax Income | -$3,512 | -$8,060 | -$6,243 | -$16,024 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,512 | -$8,060 | -$5,957 | -$16,518 |
| % Margin | -4,985.2% | -20,395% | -67,120.7% | -27,320.8% |
| EPS | -0.011 | -0.035 | -0.036 | -0.13 |
| % Growth | 68.9% | 1.7% | 72.3% | – |
| EPS Diluted | -0.011 | -0.035 | -0.036 | -0.13 |
| Weighted Avg Shares Out | 318,895 | 227,691 | 165,468 | 131,540 |
| Weighted Avg Shares Out Dil | 318,895 | 227,691 | 165,468 | 131,540 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $636 | $1,205 | $1,876 | $743 |
| Depreciation & Amortization | $432 | $427 | $426 | $2,116 |
| EBITDA | -$2,444 | -$6,428 | -$3,940 | -$13,165 |
| % Margin | -3,468.6% | -16,265.7% | -44,398.9% | -21,775.3% |